New hope for hard-to-treat breast cancer: SKB264 takes on chemo in phase 3 trial
NCT ID NCT07071337
First seen Jan 06, 2026 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This study tests a new drug called SKB264 against standard chemotherapy for people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to hormone therapy. About 430 adults aged 18-75 will be randomly assigned to receive either SKB264 or a chemotherapy chosen by their doctor. The goal is to see if SKB264 can delay cancer growth better than chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Fifth Medical Center of the Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100039, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.